Centerview Partners

Transactions

Our broad-based transaction experience extends across a range of situations, industries and enterprise values

AtaiBeckley

Announced: July 16, 2026
Value: $3.9bn
Status: Pending

Centerview as Financial Advisor to AtaiBeckley on its sale to Eli Lilly

Thomson Reuters

Announced: July 14, 2026
Value: $500mm
Status: Pending

Centerview as Exclusive Financial Advisor to Thomson Reuters on its sale of a 51% equity stake in its Global Prints business to KKR.

PANTHERx Rare

Announced: July 13, 2026
Status: Pending

Centerview as Lead Financial Advisor to PANTHERx Rare on its sale to Warburg Pincus-Led Investor Group.

Memo Therapeutics

Announced: July 1, 2026
Value: $800mm
Status: Pending

Centerview as exclusive financial advisor to Memo Therepeutics on their sale to Ipsen

Schneider Electric

Announced: June 30, 2026
Value: $3.1bn
Status: Pending

Centerview as exclusive financial advisor to Schneider Electric on their acquisition of Cognite

Nuvalent

Announced: June 9, 2026
Value: $10.6bn
Status: Pending

Centerview partners as exclusive financial advisor to Nuvalent

Standard BioTools

Announced: June 8, 2026
Value: $460mm
Status: Pending

Centerview as Financial Advisor to Standard BioTools on Merger with Treeline Biosciences

Our Capabilities

Centerview Partners takes a “One Firm” approach to deliver unmatched intellectual capital and integrity to all of our clients. We have industry-leading expertise in:

Career Opportunities

At Centerview Partners, our success depends on our people, and we are always looking for talented individuals. Please let us know if you would like to learn more about a career at Centerview.

Our Team

Our Partners have worked on many of the largest and most complex transactions and corporate situations around the globe over the course of their careers. Learn more about who we are.